CervoMed completed enrollment in its Phase 2a trial of neflamapimod for nonfluent variant primary progressive aphasia and will present interim biomarker data at CTAD.
Key Highlights:
- Completed enrollment of 25 participants in Phase 2a nfvPPA study evaluating safety, PK and clinical effects.
- Participants received oral neflamapimod: 40 mg TID (n=19) or 80 mg BID (n=6) for 24 weeks plus 12-week randomized extension.
- Interim biomarker data to be presented at the 19th CTAD conference, Nov 16–19, 2026 (Poster ID P441).
- Recent Nature Neuroscience preclinical data support p38α inhibition by neflamapimod as a potential therapeutic approach for tau-driven FTD.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.